Analysis: Shareholder activists' influence on biotechs yields mixed results

02/8/2010 | Wall Street Journal, The

Shareholder activists' growing interest in biotech firms is seen as an indication toward better returns, but their desire to force companies to adopt the business model of traditional drugmakers has not always improved companies' financial situations, according to this Dow Jones Newswires report. While the involvement of Carl Icahn proved successful for MedImmune and ImClone Systems, stocks of Biogen Idec, Amylin Pharmaceuticals and PDL Biopharma have declined since activists became involved in their operations.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care